What Is Sirtuins

Sirtuins are a family of seven NAD+-dependent deacetylase enzymes (SIRT1 through SIRT7) found in virtually all mammalian cells. They remove acetyl groups from proteins, thereby altering the activity of histones, transcription factors, and metabolic enzymes involved in DNA repair, inflammation, and energy production. Because their activity depends on the ratio of NAD+ to NADH, sirtuins function as sensors of cellular metabolic state, linking nutrient availability to gene regulation.

Aging is accompanied by a decline in NAD+ levels, which reduces sirtuin activity. This decline correlates with hallmarks of aging including genomic instability, mitochondrial dysfunction, chronic low-grade inflammation, and impaired cellular stress responses. Sirtuins sit at an intersection of several of these hallmarks, making them a subject of intense research in longevity biology.

The relevance of sirtuins to longevity goes beyond any single pathway. SIRT1 regulates genes involved in fat metabolism and insulin sensitivity. SIRT3 protects mitochondria from oxidative damage. SIRT6 maintains telomere integrity and facilitates DNA double-strand break repair. When these enzymes lose their co-substrate and slow down, the cumulative effect is a cell that is less able to repair itself, less metabolically flexible, and more prone to the dysfunctions associated with aging. Understanding sirtuins therefore means understanding one of the core regulatory networks that determines how gracefully or poorly cells age.

Sirtuins catalyze a reaction in which an acetyl group is transferred from a lysine residue on a target protein to NAD+, producing nicotinamide and O-acetyl-ADP-ribose as byproducts. This deacetylation changes the target protein's shape and function. When sirtuins deacetylate histones (the proteins that DNA wraps around), they compact chromatin structure and silence gene expression in specific regions. When they deacetylate transcription factors like p53, FOXO, or PGC-1α, they modify pathways governing apoptosis, antioxidant defense, and mitochondrial biogenesis.

The dependence on NAD+ is the central feature of sirtuin biology. NAD+ levels drop with age, partly because of increased consumption by another NAD+-dependent enzyme family called PARPs (poly-ADP-ribose polymerases), which are activated by accumulating DNA damage. As PARPs consume more NAD+ to repair damaged DNA, less NAD+ remains available for sirtuins. This creates a competition that gradually shifts the balance away from sirtuin-mediated maintenance. The enzyme CD38, which also degrades NAD+, increases in expression with age and chronic inflammation, further depleting the pool.

Each of the seven sirtuins has a distinct subcellular location and set of targets. SIRT1, the most studied, resides in the nucleus and cytoplasm. It deacetylates PGC-1α to stimulate mitochondrial production, modulates NF-κB to suppress inflammatory signaling, and adjusts insulin signaling through deacetylation of IRS-2. SIRT3, located in the mitochondrial matrix, activates superoxide dismutase 2 (SOD2) and isocitrate dehydrogenase 2, protecting against reactive oxygen species. SIRT6 occupies a specialized role in genome maintenance: it localizes to sites of DNA damage, recruits repair machinery, and regulates telomeric chromatin. Mouse studies in which SIRT6 is deleted result in severe premature aging, while overexpression of SIRT6 has extended male mouse lifespan in certain genetic backgrounds.

Sirtuin biology has matured from its early phase of dramatic lifespan claims into a more grounded field focused on mechanism and tissue specificity. Researchers now recognize that sirtuins do not function as a single longevity switch but as a family of enzymes with overlapping yet distinct roles, and that context matters enormously. SIRT6, for example, appears more directly tied to lifespan in mammals than SIRT1, reversing early assumptions. Pharmaceutical companies have pursued sirtuin-activating compounds (STACs) since the mid-2000s, but the most prominent effort, by Sirtris Pharmaceuticals (acquired by GlaxoSmithKline), was ultimately discontinued after clinical compounds failed to show clear efficacy in human metabolic disease trials.

The focus has shifted toward the NAD+ side of the equation. Rather than trying to directly activate sirtuins with small molecules, much current work centers on replenishing the NAD+ pool through precursor supplementation or inhibition of NAD+-consuming enzymes like CD38. Several clinical trials of NMN and NR are underway or recently completed, measuring endpoints such as muscle function, insulin sensitivity, and vascular health. Meanwhile, basic research continues to uncover new sirtuin substrates and regulatory mechanisms, with SIRT7's role in ribosome biogenesis and stem cell maintenance receiving increasing attention.

No drug specifically targeting sirtuin activation is currently approved for clinical use. The primary commercially available approaches to supporting sirtuin function are NAD+ precursor supplements, specifically NMN and NR, which are sold as dietary supplements and widely available without prescription. Resveratrol, pterostilbene, and fisetin are also marketed as sirtuin activators, though their mechanisms are broader and less sirtuin-specific than often claimed.

Some longevity clinics offer NAD+ intravenous infusions, which deliver the coenzyme directly rather than through precursor conversion. These infusions are available in many countries but are not standardized in dosing or protocol. Epigenetic clock testing and metabolomic panels, offered through specialized labs, can provide indirect readouts of the metabolic pathways sirtuins influence, though no commercially available test directly measures sirtuin enzymatic activity in a clinically validated way. The most accessible and evidence-supported sirtuin activators remain lifestyle interventions: caloric restriction, time-restricted eating, and regular exercise.

Sirtuins represent one of the most studied nodes in the network connecting metabolism, genome maintenance, and aging. As tools for measuring NAD+ metabolism and epigenetic age become more refined, it will become possible to evaluate whether sirtuin-targeting interventions actually shift biological aging trajectories in humans rather than just improving biomarkers in the short term. This is the key unanswered question.

The convergence of sirtuin biology with adjacent fields adds to its long-term significance. Sirtuin activity intersects with AMPK signaling, mTOR regulation, and autophagy, meaning that a deeper understanding of sirtuins informs the broader map of how cells decide to grow, repair, or recycle. If researchers can identify which sirtuins to activate (and when to activate them) in a tissue-specific manner, it could enable more precise interventions than broad-spectrum approaches like caloric restriction. Gene therapy and tissue-targeted delivery systems may eventually allow selective sirtuin modulation, though these applications remain in early preclinical stages. For now, sirtuins serve as a biological framework that explains why some of the oldest and simplest longevity practices, like eating less and moving more, affect aging at the molecular level.

Sirtuin research began in the 1990s with the discovery that the yeast gene SIR2 (silent information regulator 2) could extend replicative lifespan when overexpressed. This finding generated considerable interest, though subsequent work revealed that some early lifespan extension results in simple organisms were confounded by genetic background effects, leading to retractions and corrections. In mammals, the evidence is more nuanced. SIRT6 overexpression has extended lifespan in male mice in multiple independent studies. SIRT1 overexpression has improved metabolic health in mice without consistently extending maximum lifespan. Caloric restriction, which robustly extends lifespan in many species, increases SIRT1 activity, but whether SIRT1 is necessary for the benefits of caloric restriction remains debated; some knockout studies suggest it is important but not sufficient.

Human evidence is largely observational and mechanistic rather than interventional. Studies have found that NAD+ levels decline with age in human tissues, and that markers of sirtuin activity correlate with metabolic health. Clinical trials of NAD+ precursors (NMN and NR) have shown these compounds can raise blood NAD+ levels in humans, but whether this translates into meaningful changes in sirtuin-dependent outcomes like DNA repair rates or inflammatory gene silencing has not been conclusively demonstrated in long-term controlled trials. Resveratrol, once promoted as a direct SIRT1 activator, has a more complex pharmacology than originally thought; its sirtuin-activating effect appears to be indirect and dependent on AMPK signaling in many contexts. The field is active but has moved from initial excitement toward a more careful dissection of which sirtuins matter most, in which tissues, and at which stages of life.

Sirtuin-targeting interventions carry few known serious risks when approached through lifestyle measures like fasting and exercise. NAD+ precursor supplements (NMN and NR) have shown acceptable safety profiles in short-term human trials, though long-term safety data are limited. There is a theoretical concern that boosting NAD+ could support the survival of pre-cancerous cells, since cancer cells also rely on NAD+ for rapid proliferation; this concern is based on animal data and has not been confirmed as a clinical risk in humans. Individuals with active malignancies or a history of cancer should discuss NAD+-boosting strategies with a clinician familiar with the current evidence. High-dose resveratrol can cause gastrointestinal discomfort and may interact with blood-thinning medications.